- Home
- AKBA vs WRLD Comparison
AKBA vs WRLD Comparison
Compare AKBA & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- WRLD
- Stock Information
- Founded
- AKBA 2007
- WRLD 1962
- Country
- AKBA United States
- WRLD United States
- Employees
- AKBA N/A
- WRLD N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- WRLD Finance: Consumer Services
- Sector
- AKBA Health Care
- WRLD Finance
- Exchange
- AKBA Nasdaq
- WRLD Nasdaq
- Market Cap
- AKBA 861.7M
- WRLD 859.5M
- IPO Year
- AKBA 2014
- WRLD 1991
- Fundamental
- Price
- AKBA $2.88
- WRLD $176.68
- Analyst Decision
- AKBA Strong Buy
- WRLD
- Analyst Count
- AKBA 5
- WRLD 0
- Target Price
- AKBA $6.90
- WRLD N/A
- AVG Volume (30 Days)
- AKBA 2.9M
- WRLD 52.9K
- Earning Date
- AKBA 11-06-2025
- WRLD 10-24-2025
- Dividend Yield
- AKBA N/A
- WRLD N/A
- EPS Growth
- AKBA N/A
- WRLD 10.95
- EPS
- AKBA N/A
- WRLD 14.92
- Revenue
- AKBA $203,733,000.00
- WRLD $567,706,032.00
- Revenue This Year
- AKBA $43.91
- WRLD N/A
- Revenue Next Year
- AKBA $32.09
- WRLD $3.55
- P/E Ratio
- AKBA N/A
- WRLD $12.35
- Revenue Growth
- AKBA 16.75
- WRLD 0.80
- 52 Week Low
- AKBA $1.26
- WRLD $104.99
- 52 Week High
- AKBA $4.08
- WRLD $185.48
- Technical
- Relative Strength Index (RSI)
- AKBA 47.89
- WRLD 53.71
- Support Level
- AKBA $2.83
- WRLD $174.59
- Resistance Level
- AKBA $3.02
- WRLD $179.60
- Average True Range (ATR)
- AKBA 0.12
- WRLD 5.89
- MACD
- AKBA 0.03
- WRLD 0.21
- Stochastic Oscillator
- AKBA 56.94
- WRLD 54.93
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.